Aastrom Biosciences patents cassette approach to growing human cells.
"Our proprietary cassette approach to producing cells provides a unique, sterilely-closed environment for the automated, Good Manufacturing Practice (GMP)-compliant production of highly functional and robust cells," said R. Douglas Armstrong, PhD, President and Chief Executive Officer of Aastrom. "We continue to broaden our diverse intellectual property base that includes our processes for growing human cells, our proprietary devices to implement those processes at clinical scale, and importantly our clinical systems to automate the cell production process in compliance with GMP's."
The field of cell therapy is being fueled by numerous discoveries for growing and producing human stem and other cells that can then be used as therapeutic treatments. However, developing a standard means for producing these cells with high reliability and under conditions that are compliant with the increasingly strict regulatory requirements, has become a major limitation to moving these research laboratory discoveries into general medical use. The cell cassette covered by Aastrom's new patent , when operated with the other closed-system components of the AastromReplicell System, is being developed as an effective means to overcome this general limitation.
Aastrom is pioneering the development of proprietary cell therapeutics and cell products based on its dual-technology platforms: patented "single-pass perfusion" providing cells with enhanced biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicell System that is designed to uniquely standardize and automate the processes involved in producing high quality therapeutic cells. Aastrom is developing the DC-I dendritic cell product for use in the rapidly emerging cancer vaccine market, and the OC-I bone progenitor cell product for the treatment of degenerative bone diseases such as osteoporosis. The AastromReplicell System, the SC-I bone marrow stem cell product and the CB-I cord blood cell product have received CE Mark approval necessary for European marketing and are in late-stage United States clinical trials. These products are not available for sale at this time in the United States, except for research or investigational use.
|Printer friendly Cite/link Email Feedback|
|Comment:||Aastrom Biosciences patents cassette approach to growing human cells.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||May 1, 2001|
|Previous Article:||Biotransplant and Massachusetts General announce link between blood cells and transplantation tolerance.|
|Next Article:||Myriad Genetics awarded cancer gene patents.|